Category: 3. Business

Deloitte Wins Eighth Consecutive “Tax Technology Firm of the Year” at 2025 ITR Americas Tax Awards, Sweeping Nine Total Categories
ITR recognized Deloitte for distinction across several categories, including technology, policy and transfer pricing

NEW YORK, Oct. 27, 2025 /PRNewswire/ — Deloitte announced today that it has received nine total awards at the 2025 International Tax Review (ITR) Americas Tax Awards, highlighting achievements in delivering best-in-class tax solutions and services. This year’s slew of awards recognized work spanning tax technology, tax policy, transfer pricing and more, highlighting the combination of Deloitte’s wide-ranging tax prowess and tech-forward approach.

Award Highlights:
- Tax Advisory Firm of the Year
- Tax Technology Firm of the Year
- Tax Policy Firm of the Year
- Tax Compliance & Reporting Firm of the Year
- Indirect Tax Firm of the Year
- North America Tax Advisory Firm of the Year
- Transfer Pricing Advisory Firm of the Year
- North America Transfer Pricing Advisory Firm of the Year
- US Transfer Pricing Firm of the Year
“These recognitions across our practice are a testament to our organization’s enduring commitment to excellence, innovation, and purpose,” said Carin Giuliante, chair and CEO, Deloitte Tax LLP. “They reflect the deep experience and the collaborative spirit that define our teams. Each award is not just a milestone, but an affirmation of how our people consistently transform bold ideas into meaningful impact for our clients. I am deeply proud of the ingenuity, integrity, and purpose-driven leadership that continue to elevate our organization.”

“Transformation is not simply about adopting new technologies, it’s about reshaping how we think, collaborate, and lead,” said Chuck Kosal, chief transformation officer, Deloitte Tax LLP. “These awards reflect the ingenuity of our teams who don’t just implement change, they architect it. From pioneering AI-powered applications to reimagining global compliance platforms, I’m proud that our approach to innovation continues to set new standards across the profession.”

Deloitte continues to set the standard for tax innovation, earning consistent industry recognition for cutting-edge solutions and digital transformation services in tax. Of Deloitte’s many ITR submissions this year, highlights include:
- Deloitte’s IncentivesHub platform, which applies AI to help automate compliance and support deep data analysis. Armed with award-winning modules, like the Prevailing Wage and Apprenticeship solution and the Tax Incentive Opportunity Insights tool, IncentivesHub helps tax professionals efficiently identify tax credits and incentives, keeping pace with regulatory demands and helping optimize financial outcomes.
- A major leap forward in tax technology, Deloitte’s Indirect Tax Compliance (ITC) platform integrates AI-powered robotic process automation (RPA) to streamline entire indirect tax workflows, from data intake to e-filing and reconciliation. By automating millions of tax records and enabling real-time collaboration and transparency, the ITC platform transforms a traditionally fragmented process into a unified, efficient, and secure system, helping set a new standard for indirect tax compliance in the digital age.
- Deloitte’s GenAI Incubator Lab & Client Pilot Program is empowering organizations to develop AI-powered tax applications that drive transformative changes in their tax and accounting operations. This initiative further positions Deloitte as a pioneer in responsible AI innovation, delivering real-world impact through collaborative experimentation.
- With the launch of GAIN (GlobalAdvantage Incentives) 3.0 platform, a next-level solution for addressing tax withholding for employee incentive compensation, Deloitte has reimagined its global incentive compensation tax solution. Built on modern architecture and informed by real-world insights, GAIN 3.0 delivers enhanced speed, scalability, and intelligence, helping multinational organizations manage tax withholding for employee incentives with greater precision and efficiency.
“At Deloitte Tax, we see technology as a catalyst for empowering tax professionals to solve complex challenges with greater speed and confidence,” said Nathan Andrews, technology innovation leader at Deloitte Tax. “We are committed to offering solutions that not only advance efficiency, but also foster trust, transparency, and agility in every engagement. This year’s awards from ITR demonstrate our continued dedication to pioneering innovations that help organizations adapt to change and deliver impact at scale.”

Deloitte’s recognition in tax policy highlights its work in helping clients interpret and respond to complex domestic and global tax developments. Through a multidisciplinary lens, Deloitte provides insight and clarity organizations need to navigate change with confidence. Award-winning work this year included:
- Deloitte Tax Policy Leadership: Deloitte continues to lead the way in helping clients understand and plan for domestic and international tax policy changes. The firm’s multidisciplinary approach helps organizations navigate complex tax landscapes with confidence and clarity.
- Deloitte’s Pillar Two Agent is a breakthrough compliance solution designed to meet the demands of new global tax regulations. Featuring a robust audit trail, intuitive dashboard, and advanced analytics, the platform equips teams with the insights needed to help tax departments navigate Pillar Two requirements confidently and effectively.
The 2025 ITR Americas Awards recognize efforts that pioneered novel approaches in the tax industry and were executed between January 2024 and January 2025.

About Deloitte

Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an impact that matters for our people, clients, and communities. We bring together distinct talents, technologies, disciplines, and an ecosystem of alliances to help tackle today’s most complex business challenges and drive long-term progress. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 180 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 470,000 people worldwide connect for impact at www.deloitte.com.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

SOURCE Deloitte
Continue Reading
October 27, 2025
Meet the Newest Artificial Intelligence (AI) Stock in the Dow Jones. It Has Soared 268% Since Early Last Year, and It’s Still a Buy Right Now, According to Wall Street
Nvidia is the newest member of the Dow Jones, providing the index with some much-needed exposure to the technology sector.

While Nvidia stock has risen by almost 300% since early 2024, several powerful catalysts could fuel shares even higher.

Wall Street is overwhelmingly optimistic on Nvidia stock.

10 stocks we like better than Nvidia ›

The Dow Jones Industrial Average is home to some of the most storied, iconic American brands. Companies such as Coca-Cola, Disney, Home Depot, IBM, and Walmart are just a handful of the index’s components.

About a year ago, the Dow shook things up, replacing longtime member Intel with semiconductor giant Nvidia (NASDAQ: NVDA). From a structural standpoint, the change makes sense. Over the last few years, Intel has struggled to keep pace with its peers in the chip space. Meanwhile, Nvidia has essentially become the ultimate barometer of the stock market’s latest megatrend: The artificial intelligence (AI) revolution.

Since last January, shares of Nvidia have gained nearly 270% as of this writing (Oct. 23). For perspective, this is more than five times the gains generated in the Nasdaq Composite and S&P 500.

NVDA data by YCharts.

While this type of momentum might have you thinking the Nvidia train is headed for a speed bump, analysts across Wall Street beg to differ. Let’s explore several key tailwinds that could help fuel Nvidia’s generational run even further, and assess why now still looks like a great time for long-term investors to double down on the stock.

For the last three years, Nvidia’s primary source of revenue and profits has been its compute and networking business. This is the segment of the company responsible for selling high-performance AI accelerators, known as graphics processing units (GPUs), and accompanying data center services.

Right now, Nvidia’s next-generation chip architecture — dubbed Blackwell — is in high demand among big tech hyperscalers like Microsoft, Alphabet, Amazon, Meta Platforms, Oracle, and OpenAI. What’s even more encouraging, however, is Nvidia’s pace of innovation. Over the next couple of years, the company is slated to release even more powerful successor chips, known as Blackwell Ultra and Vera Rubin.

This dense product roadmap brings up an important question: Why is Nvidia already planning next-generation hardware as it currently scales Blackwell?

The answer to that can be summed up by looking at the long-term forecasts of capital expenditures (capex) from the hyperscalers. Over the last few years, cloud hyperscalers and big tech titans have poured hundreds of billions of dollars into AI data centers, packing these facilities with best-in-class GPU clusters and networking equipment.
AMZN Capital Expenditures (TTM) data by YCharts.

These dynamics have served as a bellwether for Nvidia throughout the AI boom. But according to Wall Street, the AI infrastructure revolution is just getting started.

According to management consulting firm McKinsey & Company, an estimated $7 trillion is expected to be spent on AI infrastructure over the next five years. In the near term, research from Goldman Sachs indicates that the hyperscalers will spend nearly half a trillion dollars on AI buildouts just next year.

It’s this rise in AI infrastructure that has technology analyst Beth Kindig of the I/O Fund calling for Nvidia to reach a $6 trillion valuation by 2026 — implying more than 30% upside from its current market capitalization of roughly $4.5 trillion.

Image source: Nvidia.

According to data from Yahoo! Finance, a total of 64 sell-side analysts cover Nvidia stock. Among these researchers, 59 place a rating of “buy” or an equivalent on Nvidia stock. Only one analyst rates Nvidia stock as a sell.

Image source: Getty Images.

While the topics explored above provide some qualitative details surrounding Nvidia’s bullish prospects, let’s dig into the numbers to add some quantitative color around why so many on Wall Street still see Nvidia stock as an attractive value.

A valuation metric that I like to look at is the forward price-to-earnings (P/E) multiple. This ratio accounts for projected earnings growth in a company — potentially giving investors a glimpse of how optimistic Wall Street is over a company’s future profit potential.

NVDA PE Ratio (Forward) data by YCharts.

In the chart above, investors can see how Nvidia’s forward P/E has fluctuated throughout the AI revolution. Two key details stick out from the analysis above.

First, Nvidia stock has clearly enjoyed some outsized momentum over the last few months, leading to a prolonged period of valuation expansion. That said, the company’s forward earnings multiple of 40 is materially lower than the prior peak of 51, witnessed early last year.

This is an important nuance to digest. What the trends above are implying is that despite having more tailwinds behind it now — and a greater ability to command even more record profits — Nvidia stock is actually cheaper today than it was in early 2024.

In this case, I am aligned with Wall Street. I think Nvidia is poised to benefit from numerous secular tailwinds as the AI infrastructure boom accelerates. While the stock is not inexpensive, per se, it trades at a relative discount compared to earlier stages of the AI revolution. That makes it an attractive buy-and-hold opportunity for long-term investors right now.

Before you buy stock in Nvidia, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $590,357!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,141,748!*

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of October 20, 2025

Adam Spatacco has positions in Alphabet, Amazon, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Goldman Sachs Group, Home Depot, Intel, International Business Machines, Meta Platforms, Microsoft, Nvidia, Oracle, Walmart, and Walt Disney. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft, short January 2026 $405 calls on Microsoft, and short November 2025 $21 puts on Intel. The Motley Fool has a disclosure policy.

Meet the Newest Artificial Intelligence (AI) Stock in the Dow Jones. It Has Soared 268% Since Early Last Year, and It’s Still a Buy Right Now, According to Wall Street was originally published by The Motley Fool
Continue Reading
October 27, 2025
5 Things to Know Before the Stock Market Opens

Stock futures are pointing to a sharply higher open this morning after major indexes closed last week at record highs; investor sentiment is getting a boost after President Donald Trump said he was optimistic the U.S. would reach a trade deal with China and address ownership of social media app TikTok; Avidity Biosciences (RNA) shares are surging after Swiss pharmaceutical maker Novartis (NVS) said it would acquire the biotechnology firm; and U.S.-listed shares of Argentine companies are soaring after President Javier Milei’s political party posted victories in legislative elections there. Here’s what you need to know today.

1. Major Stock Indexes Poised to Open Higher After Hitting Record Highs

Stock futures are higher this morning amid optimism about an apparent easing of trade tensions between the U.S. and China, while investors prepare for an expected rate cut by the Federal Reserve and a flurry of earnings reports from major technology companies later in the week. The three major U.S. stock indexes come into today’s session at record highs after each gained about 2% last week following a mild inflation report that reaffirmed expectations that the Fed will cut its key rate on Wednesday. Futures tied to the Dow Jones Industrial Average were up 0.5% recently, while those linked to the the benchmark S&P 500 and the tech-heavy Nasdaq added 0.9% and 1.3%, respectively. Bitcoin was trading at $115,400, up from a low over the weekend around $111,000. Gold futures were down 2.6% at $4,030 an ounce, as the precious metal continues to step back from recent highs. The yield on the 10-year Treasury note, which affects borrowing costs on a wide array of consumer loans, rose to 4.02% from 4.00% at Friday’s close. Crude oil futures were down slightly at around $61.40 after jumping last week following a move by the U.S. to place sanctions on Russian oil firms.

2. Trump Sounds Positive Note on U.S.-China Trade Talks

President Donald Trump said early Monday that the U.S. is positioned to reach a trade deal with China, as the the president gets set to meet with Chinese leader Xi Jinping on Thursday in South Korea. “I have a lot of respect for President Xi, and we are going to come away with the deal,” Trump said. U.S. and Chinese negotiators over the weekend reached a framework for a trade deal that could result in a reduction of tariffs and trade barriers between the two countries. The deal will reportedly delay the implementation of 100% tariffs on Chinese imports that were slated to begin on Nov. 1, while China’s export controls on rare earth elements are also expected to be delayed as the two sides continue negotiations. Trump also expects the two countries to reach a deal on ownership of the social media app TikTok. The U.S. also announced that separate trade and mineral agreements were reached with Malaysia and Cambodia, while trade pact frameworks were struck with Thailand and Vietnam. Shares of U.S. chipmakers Nvidia (NVDA) and Advanced Micro Devices (AMD), which are seeking to sell into Chinese markets, were both up more than 2% in premarket trading.

3. Trump Says Canada Will Face Additional 10% Tariffs for Reagan Ad

Trump said that the U.S. will slap an additional 10% tariff on Canadian goods after the Ontario provincial government ran an ad criticizing tariffs during the World Series on Friday. Ontario Premier Doug Ford said that broadcasts of the ad would end on Monday. Trump has criticized the ad for featuring comments from former President Ronald Reagan, which he described as a “serious misrepresentation of the facts.” Trump had placed a tariff of 35% on Canadian goods not covered by the USMCA agreement, though tariffs on some products like steel and aluminum are subject to levies of 50%. Trump had previously said trade negotiations with Canada would be “terminated” over the ad.

4. Novartis Agrees to Acquire Biotech Firm Avidity Biosciences

Shares of Avidity Biosciences (RNA) are soaring in premarket trading after Swiss pharmaceutical giant Novartis (NVS) agreed to buy the biotechnology company in a deal valued at $12 billion. Avidity will spin off part of its early-stage precision cardiology business before closing the deal in the first half of 2026, Novartis said in a statement. “The Avidity team has built robust programs with industry-leading delivery of RNA therapeutics to muscle tissue,” Novartis CEO Vas Narasimhan said. “We look forward to developing these programs to meaningfully change the trajectory of diseases for patients.” Shares of Avidity jumped more than 40% ahead of the opening bell, while Novartis shares were down about 1%.

5. U.S.-Listed Argentine Shares Rise on President Milei’s Legislative Victory

Shares of U.S.-listed Argentine companies are surging after President Javier Milei’s La Libertad Avanza party won a landslide legislative victory. President Donald Trump had offered to provide financial support for Argentina but said that the bailout hinged on the outcome of the election. “BIG WIN in Argentina for Javier Milei, a wonderful Trump Endorsed Candidate?,” Trump said on Truth Social. Shares of financial services companies Grupo Financiero Galicia SA (GGAL), Banco BBVA Argentina SA (BBAR) and Banco Macro SA (BMA) each gained more than 30% in premarket trading. Shares of oil company YPF (YPF) jumped about 25%, while shares of e-commerce firm MercadoLibre (MELI) added 7%.

Continue Reading

October 27, 2025
Bessent lists Fed chair finalists, Trump says decision by end of year

U.S. Treasury Secretary Scott Bessent speaks to reporters at the White House in Washington, D.C., Oct. 22, 2025.

Kevin Lamarque | Reuters

Treasury Secretary Scott Bessent on Monday confirmed that the list of candidates to replace Federal Reserve Chair Jerome Powell has been winnowed down to five, and President Donald Trump said the replacement is likely to be named by the end of the year.

Speaking to reporters on Air Force One, Bessent said the finalists are current Fed Governors Christopher Waller and Michelle Bowman, National Economic Council Director Kevin Hassett, former Fed Governor Kevin Warsh, and BlackRock executive Rick Rieder, according to several media outlets.

Those names were reported earlier this month by CNBC.

Bessent, who had been rumored to be a top candidate as well, said he has been conducting interviews and that he expects to do one more round before presenting a “good slate” to Trump after the Thanksgiving holiday.

Trump, also speaking to reporters Monday on Air Force One, said he anticipates naming a replacement by the end of the year. Powell’s term doesn’t expire until May. Powell then can either step down from the Fed entirely or continue serving a term as governor that lasts until 2028.

The Federal Open Market Committee meets this week, with an interest rate decision due Wednesday. Markets are pricing in a near certainty that the committee will lower its benchmark overnight borrowing rate by a quarter percentage point, which would follow a similar cut in September.

Trump has three appointees on the seven-member board of governors: Waller and Bowman, as well as Stephen Miran, who is filling an unexpired term that ends in January. Miran, who was confirmed in September as the head of the Council of Economic Advisers, is not expected to be reappointed. He has campaigned for the FOMC to be more aggressive in easing.

Should Powell opt to leave the Fed, that would give Trump four appointees. Trump thus far has been unsuccessful in trying to remove Governor Lisa Cook from the board. A rotating cast of five regional presidents joins the governors as voters during the FOMC meeting.

Continue Reading

October 27, 2025
Gold falls as potential US-China trade deal dents safe-haven demand – Reuters
1. Gold falls as potential US-China trade deal dents safe-haven demand Reuters
2. Gold declines as US-China trade optimism offsets Fed rate cut bets FXStreet
3. Gold prices slide further as easing US-China tensions curb haven demand Investing.com
4. US debt accelerates through $38 trillion: Has gold peaked? KITCO
5. A Gold Crash Everyone Saw Coming Lures Bargain Hunters Worldwide Bloomberg.com
Continue Reading
October 27, 2025
Nissan pools carbon emissions with electric vehicle maker BYD to avoid EU penalties | Electric, hybrid and low-emission cars

The Japanese carmaker Nissan is to team up with its Chinese electric vehicle rival BYD in an attempt to offset their carbon emissions and avoid EU penalties for 2025, it has confirmed.

It is part of a wider offsetting scheme the EU has sanctioned for the car industry that could help manufacturers of combustion engine cars head off an estimated £13bn in fines.

Nissan said in a statement: “Nissan has formed a pool with BYD for its CO₂ fleet emissions in Europe for the 2025 calendar year. The scope of the agreement covers passenger vehicles within EU markets and will contribute to Nissan’s commitment towards zero emissions in a sustainable way, while continuing to support the EU’s 2050 decarbonisation target.”

It added that it had entered into the agreement to “ensure the business is better able to comply with EU regulations and continue the transition towards our own goal of zero emissions”.

Chinese exports of EVs to the EU are already posing an existential crisis to the European car industry but are now, like Tesla, helping traditional car firms meet their decarbonisation targets courtesy of an EU regulation that in effect allows car firms to “pool” emissions.

The EU has already extended the period for compliance with emissions rules from one year to three years, fuelling fears this will further delay the already slow take-up of EVs in the EU, particularly in southern Europe, but also in key states such as France and Germany.

Fredrik Eklund, responsible for carbon credits trading at the Chinese-owned Swedish brand Polestar, which only makes electric vehicles, said: “It risks delaying the transition from legacy cars to EVs. We are already seeing car manufacturers pushing at the 2027 expiry date, but from our point of view and from the point of view of society, we really don’t want to delay this.”

Under the rules, car manufacturers have to meet emissions targets of 93.6g of CO₂ per kilometre.

But under the car pooling arrangement, car manufacturers can pay electric car companies to use their zero emissions record to average out the pollution from sales of their combustion engine cars to avoid fines.

The industry in the past has said the 2025 emissions targets could have led to as much as €15bn (£13.03bn) in fines.

The latest car pooling agreement, confirmed by Nissan, mirrors that of other companies who have teamed up with other big name electric car brands including Tesla and Polestar.

skip past newsletter promotion

The planet’s most important stories. Get all the week’s environment news – the good, the bad and the essential

Privacy Notice: Newsletters may contain information about charities, online ads, and content funded by outside parties. If you do not have an account, we will create a guest account for you on theguardian.com to send you this newsletter. You can complete full registration at any time. For more information about how we use your data see our Privacy Policy. We use Google reCaptcha to protect our website and the Google Privacy Policy and Terms of Service apply.

after newsletter promotion

Polestar has a pooling arrangement with Mercedes-Benz, Volvo and Smart cars, while Tesla’s zero emissions record is being mopped up by Toyota, Ford, Mazda, Alfa Romeo and Suzuki.

The price car companies are paying EV firms to offset their emissions remains confidential. But in January it was reported that carbon credit sales accounted for almost 3% of Tesla’s $72bn (£54bn) total revenue in the first nine months of last year – just over £1.6bn.

The car industry is now fighting for a softening of the EU’s 2035 target for banning the sale of new combustion engine cars, arguing that the public is still not prepared to make the switch in sufficient numbers, citing lack of infrastructure in southern and central Europe as part of the problem.

Continue Reading

October 27, 2025
SLC7A11 as a bridge between ferroptosis and disulfidptosis: a promising target for tumor treatment | Cell Communication and Signaling
Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187(2):235–56. https://doi.org/10.1016/j.cell.2023.11.044.

Article
PubMed

Google Scholar
Green DR, Victor B. The pantheon of the fallen: why are there so many forms of cell death? Trends Cell Biol. 2012;22(11):555–6. https://doi.org/10.1016/j.tcb.2012.08.008.

Article
PubMed
PubMed Central

Google Scholar
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72. https://doi.org/10.1016/j.cell.2012.03.042.

Article
PubMed
PubMed Central

Google Scholar
Bannai S, Kitamura E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J Biol Chem. 1980;255(6):2372–6.

Article
PubMed

Google Scholar
Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34(2–3):139–58. https://doi.org/10.1016/j.mam.2012.10.007.

Article
PubMed

Google Scholar
Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018;38(1):12. https://doi.org/10.1186/s40880-018-0288-x.

Article
PubMed

Google Scholar
Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. https://doi.org/10.1186/s13045-019-0720-y.

Article
PubMed
PubMed Central

Google Scholar
Liu J, Xia X, Huang P, xCT:. A critical molecule that links cancer metabolism to redox signaling. Mol Ther. 2020;28(11):2358–66. https://doi.org/10.1016/j.ymthe.2020.08.021.

Article
PubMed
PubMed Central

Google Scholar
Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620. https://doi.org/10.1007/s13238-020-00789-5.

Article
PubMed

Google Scholar
Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates Disulfidptosis. Nat Cell Biol. 2023;25(3):404–14. https://doi.org/10.1038/s41556-023-01091-2.

Article
PubMed
PubMed Central

Google Scholar
Lee N, Park SJ, Lange M, et al. Selenium reduction of ubiquinone via SQOR suppresses ferroptosis. Nat Metab. 2024;6(2):343–58. https://doi.org/10.1038/s42255-024-00974-4.

Article
PubMed
PubMed Central

Google Scholar
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82. https://doi.org/10.1038/s41580-020-00324-8.

Article
PubMed
PubMed Central

Google Scholar
Lin Q, Zhou H, Zeng J, et al. Bioactive polysaccharides mediate ferroptosis to modulate tumor immunotherapy. Int J Biol Macromol. 2024. https://doi.org/10.1016/j.ijbiomac.2024.135147.

Article
PubMed

Google Scholar
Mao C, Wang M, Zhuang L, Gan B. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond. Protein Cell. 2024;15(9):642–60. https://doi.org/10.1093/procel/pwae003.

Article
PubMed
PubMed Central

Google Scholar
Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280–96. https://doi.org/10.1038/s41571-020-00462-0.

Article
PubMed

Google Scholar
Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107–25. https://doi.org/10.1038/s41422-020-00441-1.

Article
PubMed

Google Scholar
Tong X, Tang R, Xiao M, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and Cuproptosis research. J Hematol Oncol. 2022;15(1):174. https://doi.org/10.1186/s13045-022-01392-3.

Article
PubMed
PubMed Central

Google Scholar
Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673–85. https://doi.org/10.1158/2159-8290.CD-19-0338.

Article
PubMed
PubMed Central

Google Scholar
Li Y, Yan J, Zhao Q, Zhang Y, Zhang Y. ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression. Front Pharmacol. 2022;13:904314. https://doi.org/10.3389/fphar.2022.904314.

Article
PubMed
PubMed Central

Google Scholar
Bassi MT, Gasol E, Manzoni M, et al. Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system Xc-. Pflugers Arch. 2001;442(2):286–96. https://doi.org/10.1007/s004240100537.

Article
PubMed

Google Scholar
Bridges CC, Kekuda R, Wang H, et al. Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(1):47–54.

PubMed

Google Scholar
Kim JY, Kanai Y, Chairoungdua A, et al. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim Biophys Acta. 2001;1512(2):335–44.

Article
PubMed

Google Scholar
Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S. Molecular cloning and expression of human xCT, the light chain of amino acid transport system Xc-. Antioxid Redox Signal. 2000;2(4):665–71. https://doi.org/10.1089/ars.2000.2.4-665.

Article
PubMed

Google Scholar
Li S, Lu Z, Sun R, et al. The role of SLC7A11 in cancer: friend or foe? Cancers (Basel). 2022;14(13):3059. https://doi.org/10.3390/cancers14133059.

Article
PubMed

Google Scholar
Yang J, Zhou Y, Xie S, et al. Metformin induces ferroptosis by inhibiting ufmylation of SLC7A11 in breast cancer. J Exp Clin Cancer Res. 2021;40(1):206. https://doi.org/10.1186/s13046-021-02012-7.

Article
PubMed
PubMed Central

Google Scholar
Badgley MA, Kremer DM, Maurer HC, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368(6486):85–9. https://doi.org/10.1126/science.aaw9872.

Article
PubMed
PubMed Central

Google Scholar
Hong T, Lei G, Chen X, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 2021;42:101928. https://doi.org/10.1016/j.redox.2021.101928.

Article
PubMed
PubMed Central

Google Scholar
Park JW, Kilic O, Deo M, et al. CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta Neuropathol Commun. 2023;11(1):13. https://doi.org/10.1186/s40478-023-01507-y.

Article
PubMed
PubMed Central

Google Scholar
Long Y, Tao H, Karachi A, et al. Dysregulation of glutamate transport enhances Treg function that promotes VEGF blockade resistance in glioblastoma. Cancer Res. 2020;80(3):499–509. https://doi.org/10.1158/0008-5472.CAN-19-1577.

Article
PubMed

Google Scholar
Yuan L, Li S, Chen Q, et al. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma. Cell Death Differ. 2022;29(8):1513–27. https://doi.org/10.1038/s41418-022-00939-8.

Article
PubMed
PubMed Central

Google Scholar
Combs JA, DeNicola GM. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers (Basel). 2019;11(5):678. https://doi.org/10.3390/cancers11050678.

Article
PubMed

Google Scholar
Carlisle AE, Lee N, Matthew-Onabanjo AN, et al. Selenium detoxification is required for cancer-cell survival. Nat Metab. 2020;2(7):603–11. https://doi.org/10.1038/s42255-020-0224-7.

Article
PubMed
PubMed Central

Google Scholar
Lee N, Carlisle AE, Kim D. Examining xCT-mediated selenium uptake and Selenoprotein production capacity in cells. Methods Enzymol. 2022;662:1–24. https://doi.org/10.1016/bs.mie.2021.10.002.

Article
PubMed

Google Scholar
Goji T, Takahara K, Negishi M, Katoh H. Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation. J Biol Chem. 2017;292(48):19721–32. https://doi.org/10.1074/jbc.M117.814392.

Article
PubMed
PubMed Central

Google Scholar
Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24(4):450–65. https://doi.org/10.1016/j.ccr.2013.08.020.

Article
PubMed
PubMed Central

Google Scholar
Shin CS, Mishra P, Watrous JD, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8:15074. https://doi.org/10.1038/ncomms15074.

Article
PubMed
PubMed Central

Google Scholar
Romero R, Sayin VI, Davidson SM, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017;23(11):1362–8. https://doi.org/10.1038/nm.4407.

Article
PubMed
PubMed Central

Google Scholar
Bannai S. Induction of cystine and glutamate transport activity in human fibroblasts by diethyl maleate and other electrophilic agents. J Biol Chem. 1984;259(4):2435–40.

Article
PubMed

Google Scholar
Bannai S, Kitamura E. Adaptive enhancement of cystine and glutamate uptake in human diploid fibroblasts in culture. Biochim Biophys Acta. 1982;721(1):1–10. https://doi.org/10.1016/0167-4889(82)90017-9.

Article
PubMed

Google Scholar
Bannai S, Sato H, Ishii T, Taketani S. Enhancement of glutathione levels in mouse peritoneal macrophages by sodium arsenite, cadmium chloride and glucose/glucose oxidase. Biochim Biophys Acta. 1991;1092(2):175–9. https://doi.org/10.1016/0167-4889(91)90153-o.

Article
PubMed

Google Scholar
Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374–95. https://doi.org/10.15252/embr.201642195.

Article
PubMed
PubMed Central

Google Scholar
Ye P, Mimura J, Okada T, et al. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol. 2014;34(18):3421–34. https://doi.org/10.1128/MCB.00221-14.

Article
PubMed
PubMed Central

Google Scholar
Ye Y, Chen A, Li L, et al. Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification. Kidney Int. 2022;102(6):1259–75. https://doi.org/10.1016/j.kint.2022.07.034.

Article
PubMed

Google Scholar
Wang L, Liu Y, Du T, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc. Cell Death Differ. 2020;27(2):662–75. https://doi.org/10.1038/s41418-019-0380-z.

Article
PubMed

Google Scholar
Zhao X, Chen C, Qiu H, et al. The landscape of ATF3 in tumors: metabolism, expression regulation, therapy approach, and open concerns. Pharmacol Res. 2025;214:107666. https://doi.org/10.1016/j.phrs.2025.107666.

Article
PubMed

Google Scholar
Wang Y, Yang L, Zhang X, et al. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 2019;20(7):e47563. https://doi.org/10.15252/embr.201847563.

Article
PubMed
PubMed Central

Google Scholar
Zhang Y, Koppula P, Gan B. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell Cycle. 2019;18(8):773–83. https://doi.org/10.1080/15384101.2019.1597506.

Article
PubMed
PubMed Central

Google Scholar
Tsuchihashi K, Okazaki S, Ohmura M, et al. The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). Cancer Res. 2016;76(10):2954–63. https://doi.org/10.1158/0008-5472.CAN-15-2121.

Article
PubMed
PubMed Central

Google Scholar
Liu L, He J, Sun G, et al. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022;12(5):e778. https://doi.org/10.1002/ctm2.778.

Article
PubMed
PubMed Central

Google Scholar
Zhu Y, Zhang C, Huang M, Lin J, Fan X, Ni T. TRIM26 induces ferroptosis to inhibit hepatic stellate cell activation and mitigate liver fibrosis through mediating SLC7A11 ubiquitination. Front Cell Dev Biol. 2021;9:644901. https://doi.org/10.3389/fcell.2021.644901.

Article
PubMed
PubMed Central

Google Scholar
Li S, Lu Z, Sun R, et al. The role of SLC7A11 in cancer: friend or foe? Cancers (Basel). 2022;14(13):3059. https://doi.org/10.3390/cancers14133059.

Article
PubMed

Google Scholar
Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400. https://doi.org/10.1016/j.ccr.2011.01.038.

Article
PubMed

Google Scholar
Gan W, Dai X, Dai X, et al. LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat Cell Biol. 2020;22(2):246–56. https://doi.org/10.1038/s41556-020-0463-6.

Article
PubMed
PubMed Central

Google Scholar
Zhang W, Feng J, Ni Y, et al. The role of SLC7A11 in diabetic wound healing: novel insights and new therapeutic strategies. Front Immunol. 2024;15:1467531. https://doi.org/10.3389/fimmu.2024.1467531.

Article
PubMed
PubMed Central

Google Scholar
Gu Y, Albuquerque CP, Braas D, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the Cystine-Glutamate antiporter xCT. Mol Cell. 2017;67(1):128–e1387. https://doi.org/10.1016/j.molcel.2017.05.030.

Article
PubMed
PubMed Central

Google Scholar
Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85. https://doi.org/10.1016/j.cell.2017.09.021.

Article
PubMed
PubMed Central

Google Scholar
Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–8. https://doi.org/10.1038/nchembio.2239.

Article
PubMed

Google Scholar
Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81–90. https://doi.org/10.1038/nchembio.2238.

Article
PubMed

Google Scholar
Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21(5):579–91. https://doi.org/10.1038/s41556-019-0305-6.

Article
PubMed
PubMed Central

Google Scholar
Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62. https://doi.org/10.1038/nature14344.

Article
PubMed
PubMed Central

Google Scholar
Jennis M, Kung CP, Basu S, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 2016;30(8):918–30. https://doi.org/10.1101/gad.275891.115.

Article
PubMed
PubMed Central

Google Scholar
Zhang Y, Shi J, Liu X, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20(10):1181–92. https://doi.org/10.1038/s41556-018-0178-0.

Article
PubMed
PubMed Central

Google Scholar
Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79(8):1913–24. https://doi.org/10.1158/0008-5472.CAN-18-3037.

Article
PubMed
PubMed Central

Google Scholar
Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101–10. https://doi.org/10.1016/j.annonc.2021.06.001.

Article
PubMed

Google Scholar
Xiong HJ, Yu HQ, Zhang J, et al. Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice. Mil Med Res. 2023;10(1):68. https://doi.org/10.1186/s40779-023-00501-8.

Article
PubMed
PubMed Central

Google Scholar
Mueller S, Engleitner T, Maresch R, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554(7690):62–8. https://doi.org/10.1038/nature25459.

Article
PubMed
PubMed Central

Google Scholar
Hu K, Li K, Lv J, et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest. 2020;130(4):1752–66. https://doi.org/10.1172/JCI124049.

Article
PubMed
PubMed Central

Google Scholar
Lim JKM, Delaidelli A, Minaker SW, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A. 2019;116(19):9433–42. https://doi.org/10.1073/pnas.1821323116.

Article
PubMed
PubMed Central

Google Scholar
Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054–81. https://doi.org/10.1080/15548627.2020.1810918.

Article
PubMed

Google Scholar
Wang W, Green M, Choi JE, et al. CD8 + T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4. https://doi.org/10.1038/s41586-019-1170-y.

Article
PubMed
PubMed Central

Google Scholar
Kim DH, Kim WD, Kim SK, Moon DH, Lee SJ. TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 Inhibition in hepatocellular carcinoma cells. Cell Death Dis. 2020;11(5):406. https://doi.org/10.1038/s41419-020-2618-6.

Article
PubMed
PubMed Central

Google Scholar
Dai E, Han L, Liu J, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16(11):2069–83. https://doi.org/10.1080/15548627.2020.1714209.

Article
PubMed
PubMed Central

Google Scholar
Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Mol Ther. 2022;28:366–86. https://doi.org/10.1016/j.omtn.2022.03.020.

Article

Google Scholar
Qin K, Zhang F, Wang H, et al. CircRNA circSnx12 confers cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis. BMB Rep. 2023;56(2):184–9. https://doi.org/10.5483/BMBRep.2022-0175.

Article
PubMed
PubMed Central

Google Scholar
Sun C, Liu P, Pei L, Zhao M, Huang Y. Propofol inhibits proliferation and augments the anti-tumor effect of doxorubicin and paclitaxel partly through promoting ferroptosis in triple-negative breast cancer cells. Front Oncol. 2022;12:837974. https://doi.org/10.3389/fonc.2022.837974.

Article
PubMed
PubMed Central

Google Scholar
Yadav P, Sharma P, Sundaram S, Venkatraman G, Bera AK, Karunagaran D. SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells. Cancer Lett. 2021;522:211–24. https://doi.org/10.1016/j.canlet.2021.09.033.

Article
PubMed

Google Scholar
Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021;218(6):e20210518. https://doi.org/10.1084/jem.20210518.

Article
PubMed
PubMed Central

Google Scholar
Mi T, Kong X, Chen M, Guo P, He D. Inducing disulfidptosis in tumors: potential pathways and significance. MedComm (2020). 2024;5(11):e791. https://doi.org/10.1002/mco2.791
Yan Y, Teng H, Hang Q, et al. Slc7a11 expression level dictates differential responses to oxidative stress in cancer cells. Nat Commun. 2023;14(1):3673. https://doi.org/10.1038/s41467-023-39401-9.

Article
PubMed
PubMed Central

Google Scholar
Joly JH, Delfarah A, Phung PS, Parrish S, Graham NA. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem. 2020;295(5):1350–65. https://doi.org/10.1074/jbc.RA119.011471.

Article
PubMed

Google Scholar
Liu T, Ren Y, Wang Q, et al. Exploring the role of the disulfidptosis-related gene SLC7A11 in adrenocortical carcinoma: implications for prognosis, immune infiltration, and therapeutic strategies. Cancer Cell Int. 2023;23(1):259. https://doi.org/10.1186/s12935-023-03091-6.

Article
PubMed
PubMed Central

Google Scholar
Zhao D, Meng Y, Dian Y, et al. Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy. Redox Biol. 2023;68:102966. https://doi.org/10.1016/j.redox.2023.102966.

Article
PubMed
PubMed Central

Google Scholar
Li J, Yu T, Sun J, et al. Integrated analysis of disulfidptosis-related immune genes signature to boost the efficacy of prognostic prediction in gastric cancer. Cancer Cell Int. 2024;24(1):112. https://doi.org/10.1186/s12935-024-03294-5.

Article
PubMed
PubMed Central

Google Scholar
Xia Q, Yan Q, Wang Z, et al. Disulfidptosis-associated lncRNAs predict breast cancer subtypes. Sci Rep. 2023;13(1):16268. https://doi.org/10.1038/s41598-023-43414-1.

Article
PubMed
PubMed Central

Google Scholar
Liu L, Liu J, Lyu Q, et al. Disulfidptosis-associated lncRNAs index predicts prognosis and chemotherapy drugs sensitivity in cervical cancer. Sci Rep. 2023;13(1):12470. https://doi.org/10.1038/s41598-023-39669-3.

Article
PubMed
PubMed Central

Google Scholar
Korangath P, Teo WW, Sadik H, et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res. 2015;21(14):3263–73. https://doi.org/10.1158/1078-0432.CCR-14-1200.

Article
PubMed
PubMed Central

Google Scholar
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141-162. doi:10.1038/s41573-021-00339-6
Shao N, Qiu H, Liu J, et al. Targeting lipid metabolism of macrophages: a new strategy for tumor therapy. J Adv Res. 2025;68:99–114. https://doi.org/10.1016/j.jare.2024.02.009.

Article
PubMed

Google Scholar
Zhao X, Zhao J, Li D, et al. Akkermansia muciniphila: a potential target and pending issues for oncotherapy. Pharmacol Res. 2023;196:106916. https://doi.org/10.1016/j.phrs.2023.106916.

Article
PubMed

Google Scholar
Liu X, Zhuang L, Gan B. Disulfidptosis: disulfide stress-induced cell death. Trends Cell Biol. 2024;34(4):327–37. https://doi.org/10.1016/j.tcb.2023.07.009.

Article
PubMed

Google Scholar
Qiu H, Shao N, Liu J, et al. Amino acid metabolism in tumor: new shine in the fog? Clin Nutr. 2023;42(8):1521–30. https://doi.org/10.1016/j.clnu.2023.06.011.

Article
PubMed

Google Scholar
Liu J, Shao N, Qiu H, et al. Intestinal microbiota: A Bridge between intermittent fasting and tumors. Biomed Pharmacother. 2023;167:115484. https://doi.org/10.1016/j.biopha.2023.115484.

Article
PubMed

Google Scholar

Continue Reading

I recently had the pleasure of visiting the lovely mountain town of Lugano, Switzerland, whose appeal lies in that it is basically Italy but administered by the Swiss. That’s according to Tether CEO Paolo Ardoino, one of the prime backers of Plan B, a Bitcoin conference where I hosted a discussion on the growing trend of nation states embracing the original cryptocurrency.

The event had an upbeat vibe—not surprising since everyone there worshipped Bitcoin—but it was also clear there was trouble in paradise. It turns out there is a growing schism over Bitcoin’s codebase, and whether it should be modified to permit the blockchain to include more non-financial data.

The notion of including data unrelated to Bitcoin transactions is hardly new and, indeed, the very first block on the blockchain includes a reference to a newspaper headline about bank bailouts. Now, though, Bitcoin’s biggest and most influential group of coders, known as Core, are planning to tweak their software in order to significantly lift the restrictions on how much non-payment information can be included in a block.

For the Core crowd, this is a simple and pragmatic way to promote new uses for Bitcoin and, in the process, drum up extra fees for miners at a time when the blockchain’s lottery payment is 3.125 Bitcoins, and set to halve again in 2028. A fast-growing rival faction, though, wants nothing to do with the scheme and is promoting a Bitcoin client software of its own called Knots.

That faction’s software is led by an influential Bitcoin developer, who is a devout Catholic and reportedly named it Knots after the “whip of knots” Jesus used to drive money changers from a temple. According to a lawyer I spoke with on the Knots side, the software is necessary to protect the blockchain from what he decried as spammers and “scam adjacency” projects that promote things like Bitcoin NFTs.

If you’ve encountered Bitcoiners in person or online, you’re aware they’re not known for their tact. That is true of prominent figures from Bitcoin’s early days who have been denouncing each other on stage in Lugano and on X. These high profile partisans include Peter Todd and Jameson Lopp for the Core faction, and Nick Szabo and Luke Dashjr for the rival Knots sect.

This latest schism (you can read a helpful breakdown here) hearkens back to the Bitcoin block size wars that raged from 2015 to 2017, and ultimately saw the “small blockers”—who favored keeping Bitcoin blocks at 1MB—prevail over rivals who claimed boosting the blocks to 2MB or more would be more commercially viable. That fight produced bad blood that has lasted to this day.

In the current fight, Knots is still the smaller faction, but has already become the client of choice for over 20% of Bitcoin node operators. Its growing popularity lies not only in Knots’ position on expanding the blockchain, but from a perception that the Core crowd has grown arrogant and out-of-touch with Bitcoin’s core values. The Core folks, meanwhile, dismiss the Knots faction as lying trouble-makers.

I lack the authority to weigh in on much of this, other than to observe that this latest battle for the soul of Bitcoin reinforces what I’ve said for years: Bitcoin is a marvelous technology, but also a religion. And with any religion, there will be divisions between old-line believers and more modern adherents. Happily for the crowd in Lugano, there was a moment of unity that came with the unveiling of a restored Satoshi Nakamoto statue on the city’s beautiful lakefront. Bitcoin’s factions may be at war but there’s no doubt they still worship a common god.

Jeff John Roberts
jeff.roberts@fortune.com
@jeffjohnroberts

DECENTRALIZED NEWS

If you can’t beat ‘em, join ‘em: JPMorgan Chase’s CEO continues to soften his longtime anti-crypto stance as his bank announced that it will let borrowers use Bitcoin and Ethereum for loan collateral by the end of year. (Bloomberg)

COIN upgrade: Coinbase’s forthcoming crypto token could be worth $12 billion to $34 billion, said a JPM analyst, who cited the token and the slowing growth of DEXes as reasons to upgrade the stock ahead of third-quarter earnings this week. (DL News)

Here we ICO again? In assessing Coinbase’s $375 million acquisition of Echo, which was founded by crypto influencer Cobie and helps token projects raise funds, one journalist speculated it could inaugurate the return of 2016-style initial coin offerings. (Bloomberg)

DAT doesn’t add up: Following a Fortune exposé pointing to potential insider trading ahead of public company pivots to digital asset treasuries, a new report provides evidence that insiders tied to some popular DATs are using share sales to circumvent token lockups. (Unchained)

Trump picks a CFTC chair: The White House selected longtime lawyer and crypto guy Mike Selig to lead the agency. The choice of Selig, which came after the Winklevii helped torpedo the original frontrunner, was hailed by industry vets who are eager to finalize a key bill that will divide responsibilities between the SEC and CFTC. (Politico)

MAIN CHARACTER OF THE WEEK

Changpeng Zhao, cofounder of Binance.

Samsul Said—Bloomberg/Getty Images

CZ was the easy choice for main character of the week after finally securing a Presidential pardon. Critics, pointing to a $2 billion deal involving the Trump family’s stablecoin and Binance, blasted the pardon as massively corrupt while many on Crypto Twitter claimed it was fair since CZ—who pleaded guilty—had allegedly been the target of a political prosecution.

MEME O’ THE MOMENT

A screenshot of a twitter post that juxtaposes two Bitcoin statues. — In Lugano, Switzerland, Bitcoiners unveiled a refurbished statue of Satoshi Nakamoto.

Bitcoin devotees seeking to make a pilgrimage have a growing number of options. In addition to the refurbished Satoshi statue unveiled in Lugano, there is one in Budapest as well. Can a formal shrine—or perhaps a Bitcoin theme park—be far behind?

Category: 3. Business

Deloitte Wins Eighth Consecutive “Tax Technology Firm of the Year” at 2025 ITR Americas Tax Awards, Sweeping Nine Total Categories

Continue Reading

Meet the Newest Artificial Intelligence (AI) Stock in the Dow Jones. It Has Soared 268% Since Early Last Year, and It’s Still a Buy Right Now, According to Wall Street

Continue Reading

5 Things to Know Before the Stock Market Opens

1. Major Stock Indexes Poised to Open Higher After Hitting Record Highs

2. Trump Sounds Positive Note on U.S.-China Trade Talks

3. Trump Says Canada Will Face Additional 10% Tariffs for Reagan Ad

4. Novartis Agrees to Acquire Biotech Firm Avidity Biosciences

5. U.S.-Listed Argentine Shares Rise on President Milei’s Legislative Victory

Continue Reading

Bessent lists Fed chair finalists, Trump says decision by end of year

Continue Reading

Gold falls as potential US-China trade deal dents safe-haven demand – Reuters

Continue Reading

Nissan pools carbon emissions with electric vehicle maker BYD to avoid EU penalties | Electric, hybrid and low-emission cars

Continue Reading

SLC7A11 as a bridge between ferroptosis and disulfidptosis: a promising target for tumor treatment | Cell Communication and Signaling

Continue Reading

Eli Lilly buys Adverum in eye disease gene therapy punt

Discover B2B Marketing That Performs

Lilly bucks big pharma trend

Pharmaceutical Technology Excellence Awards – The Benefits of Entering

Continue Reading

Bitcoin faces a new civil war over how its blockchain should be used

DECENTRALIZED NEWS

MAIN CHARACTER OF THE WEEK

MEME O’ THE MOMENT

Continue Reading

Mitigation of alkaline stress and iron deficiency in Petunia hybrida through resveratrol-induced physiological and nutrient responses | BMC Plant Biology

Continue Reading

Category: 3. Business

1. Major Stock Indexes Poised to Open Higher After Hitting Record Highs

2. Trump Sounds Positive Note on U.S.-China Trade Talks

3. Trump Says Canada Will Face Additional 10% Tariffs for Reagan Ad

4. Novartis Agrees to Acquire Biotech Firm Avidity Biosciences

5. U.S.-Listed Argentine Shares Rise on President Milei’s Legislative Victory

Discover B2B Marketing That Performs

Lilly bucks big pharma trend

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

Pharmaceutical Technology Excellence Awards – The Benefits of Entering

DECENTRALIZED NEWS

MAIN CHARACTER OF THE WEEK

MEME O’ THE MOMENT